tousled1
12-14-2007, 10:15 PM
SAN ANTONIO, TX -- December 14, 2007 -- Women with hormone receptor-positive breast cancer who receive zoledronic acid (Zometa) at the same time that they begin aromatase inhibitor therapy are significantly less likely to develop bone loss than if they delay treatment until there are signals of decrease in bone density.
To read full article:
http://www.docguide.com/news/content.nsf/news/852571020057CCF6852573B10077AC55?OpenDocument&id=48dde4a73e09a969852568880078c249&c=Breast%20Cancer&count=10
To read full article:
http://www.docguide.com/news/content.nsf/news/852571020057CCF6852573B10077AC55?OpenDocument&id=48dde4a73e09a969852568880078c249&c=Breast%20Cancer&count=10